Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GPR27 | Q9NS67 | 8/20 | 0.52 |
| ▸ | CPT2 | P23786 | 1/20 | 0.52 |
| ▸ | CPT1A | P50416 | 1/20 | 0.52 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ACLY | P53396 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2055411 | 0.86 | KMT2A (0.54) | MEN1KMT2ASMN1; SMN2KDM4EHTT | |
| SCHEMBL1110317 | 0.85 | ACLY (0.63) | MEN1KMT2ALMNAACLY | |
| SCHEMBL1319602 | 0.84 | ACLY (0.52) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1319403 | 0.84 | KCNA5 (0.61) | MEN1KMT2AKDM4EALDH1A1ACLY | |
| SCHEMBL1110283 | 0.82 | ACLY (0.51) | KDM4EALDH1A1HPGDACLY | |
| SCHEMBL1319413 | 0.81 | RAB9A (0.60) | KDM4EALDH1A1HPGDHTTLMNA | |
| SCHEMBL1110193 | 0.80 | ACLY (0.67) | ACLY | |
| SCHEMBL10220804 | 0.79 | KMT2A (0.51) | MEN1KMT2ASMN1; SMN2KDM4EHTT | |
| SCHEMBL1110497 | 0.78 | KCNA5 (0.52) | MEN1KMT2ASMN1; SMN2ALDH1A1CPT2 | |
| SCHEMBL1319724 | 0.78 | KCNA5 (0.65) | MEN1KMT2AHPGDACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| WO-2009127723-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | SULT2A1, UGT1A1, SLC5A1 | MEN1 3970/4885KMT2A 645/4885SMN1; SMN2 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.